Multiple Sclerosis and Medical Cannabis: Clinical Evidence
Medical cannabis for multiple sclerosis has been studied mostly for spasticity, nerve pain, sleep and bladder symptoms, and the results are mixed: some people report relief, while the largest recent placebo-controlled trial found no clear difference. No trial shows that it slows MS itself. Every form that contains THC acts on the brain and can interact with MS medicines, so the decision belongs in a conversation with a physician.
Built on peer-reviewed research published from 1981 to 2026: randomized trials, observational studies and laboratory work
When MS symptoms don’t let go: spasticity, pain, fatigue and sleep
Most people with multiple sclerosis can tell you exactly which symptom runs their day. For some it is legs that stiffen and jerk at night. For others it is burning nerve pain, a bladder that sets the schedule, or a tiredness that no amount of sleep fixes. Many keep a symptom diary for years and still leave the clinic with the same list.
The standard medicines help many people, but not always enough, and not always without a price. In a large study of people with MS, 899 of 1,691 participants reported regular pain and 87.3% of them used pain medicine; 40.2% of participants had stopped at least one medicine, side effects were behind 37.6% of the stopped medicines and lack of effect behind 20.3% [1]. That is the gap where questions about cannabis usually start — and where bringing it up with a neurologist can feel awkward. This page is meant to make that conversation easier.
Which symptom wears you down most?
Pick one; this does not diagnose anything.
Spasticity and spasms: muscles that stay tight, legs that kick or cramp at night, a stiffness that makes stairs and dressing slow. It is the symptom cannabinoid research in MS has looked at most, in adults whose spasticity did not settle on other medicines [2][3]. studied in cannabinoid research
Nerve pain: burning, stabbing or electric feelings that come from damaged nerves rather than from an injury. Central neuropathic pain was a main outcome of the largest recent trial [2]. studied in cannabinoid research
Fatigue: an exhaustion that arrives without effort and does not lift with rest. In cannabis studies it shows up mostly as a side effect, and in a daily-diary study of people with MS fatigue was higher after cannabis use [4]. side effect in trials
Sleep: nights broken by spasms, pain or trips to the bathroom. A sleep-lab study followed people with MS before and after six weeks of a cannabis mouth spray [5]. studied in cannabinoid research
Bladder: urgency, frequent trips and night waking. A 2026 review pooled bladder results from studies of the cannabis mouth spray nabiximols [6]. studied in cannabinoid research
Walking and balance: heavy legs, tripping, a shorter distance before you need to stop. The same 2026 review also looked at walking measures [6] — and balance is also what cannabis can make worse. studied in cannabinoid research
What is multiple sclerosis?
Multiple sclerosis (MS) is a long-term disease in which the immune system attacks the brain, the spinal cord and the optic nerves. Its main target is myelin, the fatty coating that insulates nerve fibers, and the damaged spots heal into scars — “sclerosis” means scarring, and there are many of them [7]. MS is the most common disabling neurological disease of young adults; a 2026 review puts the number of people living with it worldwide at about 2.8 million [8].
How does MS affect the nervous system and the body? Signals that should travel along a nerve in a fraction of a second slow down, scramble or stop where myelin is lost. Which symptoms appear depends on where the damage sits: blurred or painful vision when the optic nerve is hit, numbness or weakness in the limbs, stiffness and spasms, bladder and bowel problems, trouble with balance, fatigue and changes in thinking. Over time, the nerve fibers themselves can be lost, which is what drives lasting disability [7][9].
Types of MS
Doctors describe MS by how it behaves over time. The type matters because disease-modifying treatment and the outlook differ between them [10].
| Type | What happens | How it usually changes over time | What it means for treatment |
|---|---|---|---|
| Clinically isolated syndrome (CIS) | A first episode of MS-like symptoms lasting at least a day, such as optic neuritis or numbness on one side. | Some people never have a second episode; MRI findings help judge the chance that it becomes MS. | Some people start disease-modifying treatment early if MRI shows a high risk. |
| Relapsing-remitting MS (RRMS) | Attacks (relapses) of new or worsening symptoms, followed by full or partial recovery. | The most common form at diagnosis; between relapses the disease may seem quiet. | Most disease-modifying therapies are approved for this form. |
| Secondary progressive MS (SPMS) | After a relapsing phase, disability builds up steadily, with or without relapses. | Develops in some people with RRMS, usually after years. | Fewer options; treatment depends on whether the disease is still active. |
| Primary progressive MS (PPMS) | Function worsens gradually from the start, without clear relapses. | Often begins later in life and affects walking first. | One disease-modifying therapy is approved; symptom care and rehabilitation carry much of the load. |
How MS is diagnosed
There is no single test for MS. A neurologist puts the diagnosis together step by step [7][9]:
- History and neurological exam — what happened, when, and what the exam finds in vision, strength, reflexes, sensation and balance.
- MRI of the brain and spinal cord — shows areas of damage (lesions); contrast dye shows which ones are active right now.
- The McDonald criteria — the rules neurologists use to confirm that damage has happened in different places and at different times.
- Extra tests when needed — a spinal tap to look for immune markers in the spinal fluid, evoked-potential tests of nerve signal speed, and blood tests to rule out look-alike conditions.
How long does it take to diagnose multiple sclerosis? It varies a great deal. When the first MRI already meets the criteria, the answer can come within weeks; when symptoms are vague or come and go, it can take much longer, because the criteria need proof that the disease is spreading in place and time.
Quick answers
Is multiple sclerosis an autoimmune disease?
Yes, it is considered an immune-mediated, autoimmune disease: the body’s own immune cells cross into the brain and spinal cord and damage myelin and nerve fibers. That is why most long-term treatments for MS work by calming or redirecting the immune system [7].
What causes MS?
No single cause is known. MS seems to start when several risk factors meet in one person: earlier infection with Epstein-Barr virus (the virus behind mononucleosis), low vitamin D and little sunlight, smoking, obesity in the teenage years and genes that shape the immune system [7][9]. None of these on its own causes MS.
Is MS genetic, and does it run in families?
MS is not inherited in a simple way, but the risk is higher when a parent or sibling has it. Many genes each add a little risk, most of them involved in the immune system [7]. Genetic studies of people with MS also look at depression and anxiety: polygenic scores — a combined measure of many small genetic risks — were studied against disease activity and disability worsening in one cohort and against anxiety in another [11][12]. These are background studies, not cannabis studies. Routine genetic testing for MS is not offered.
Is MS contagious? Can you catch it?
No. MS does not pass from person to person. Epstein-Barr virus, which is contagious, is a risk factor, but almost everyone catches it at some point and very few develop MS [7].
Does MS show up on an MRI?
In most people, yes: MRI shows lesions in the brain and spinal cord and is the main test for diagnosis and follow-up. A normal scan makes MS less likely but does not rule it out completely, and spots on an MRI can have other causes, such as migraine or small-vessel disease [9].
What do the EDSS and the MS Functional Composite measure?
Both are yardsticks used in clinics and trials. The Expanded Disability Status Scale (EDSS) scores disability from 0 (normal exam) to 10, weighted heavily toward walking. The MS Functional Composite (MSFC) combines a timed 25-foot walk, a pegboard test of hand function and a test of thinking speed. When a study on this page says “disability got worse,” it usually means the EDSS went up.
Can multiple sclerosis kill you? Life expectancy, remission and progression
MS itself is rarely the direct cause of death, and most people with MS live for decades after diagnosis. On average, life is somewhat shorter than for people without MS, mostly because of complications of advanced disability — infections, swallowing problems, falls — and other conditions such as heart disease. How a single person does depends on the type of MS, the age when it started, other health problems and how early effective treatment began [7][10]. Today’s outlook is better than the one many people find in old articles, because disease-modifying therapies have changed how often relapses happen.
How long does MS last?
MS is lifelong. A single relapse usually builds over days, peaks and then eases over weeks to months. The disease underneath stays, which is why treatment and follow-up continue between relapses too.
Can MS go into remission?
Yes, in the relapsing-remitting form: after a relapse, symptoms can fade partly or completely, and some people go years without a new attack, especially on treatment. Remission here means quiet disease, not that MS has gone away. Progressive forms do not have remissions in the same way, though they can stay stable for stretches [10].
How fast does MS progress?
There is no single speed. Some people have mild MS for decades; others build up disability within years. Frequent early relapses, many lesions on the first MRI, older age at onset and a progressive course from the start point to a faster course, while early disease-modifying therapy slows relapse-driven damage [7][9]. Your neurologist can tell you how your own MRI and history compare.
Does MS shorten your life?
Somewhat, on average, and much less than many people fear. Most of the difference comes from complications that can be prevented or treated — pneumonia, urinary infections, pressure sores, falls — and from heart disease, which is why exercise, not smoking and blood pressure control matter as much in MS as anywhere else [7].
Is MS curable, and can it be reversed?
Not yet. Treatments can lower the number of relapses and new lesions and slow disability, and rehabilitation can win back function. Damage that has already turned into lost nerve fibers does not grow back on any current treatment. Repairing myelin is an active research field; in cannabinoid research it has been seen only in laboratory models [8].
Living with MS: diet, exercise and supplements
The searches people make most after a diagnosis are about what they can do themselves. The honest answer: a lot of everyday choices help, none of them replaces treatment, and some popular claims run ahead of the evidence [7][9].
Diet
A heart-healthy, Mediterranean-style way of eating — vegetables, fruit, whole grains, fish, olive oil — supports overall health and weight, which matters in MS.
No special MS diet has been shown to prevent relapses or slow the disease.
Weight, constipation and bladder-friendly drinking habits before cutting out whole food groups.
Exercise
Regular aerobic, strength, stretching and balance exercise improves fitness, mood, walking and fatigue in many people with MS.
Which routine is best for each type and stage; heat can bring on a short pseudo-relapse, so cool settings and pools often work better.
A referral to a physical therapist who can build a routine around your balance and spasticity.
Supplements: vitamin D and omega-3
Low vitamin D is linked with a higher risk of MS, and doctors often check and correct it.
Whether vitamin D, omega-3 fish oil or other supplements change the course of MS once you have it.
A blood test before high doses — too much vitamin D is harmful — and every supplement you take.
Treatment and support
Disease-modifying therapies (DMTs) lower relapses and new lesions; rehabilitation, good sleep and mental health care improve daily life.
Which therapy fits a given person best over decades — it is reviewed as the disease changes.
Symptom treatment for spasticity, pain, bladder and mood alongside the DMT.
Could medical cannabis be worth discussing for your MS symptoms?
Twelve short questions about your MS, the symptom that bothers you most and your medicines. Your answers stay on this page and show what to bring to your neurologist.
12 questions · about a minute · your answers stay in this browser
Why cannabis comes up in MS care
The body has its own cannabinoid system — the endocannabinoid system — a network of signaling molecules and receptors that helps set muscle tone, pain signals and inflammation. Its two best-known receptors are CB1, found mostly on nerve cells, and CB2, found mostly on immune cells. Researchers began to look at cannabinoids in MS because both of these targets sit exactly where MS does its damage: in the nerve pathways that control movement and in the immune cells that attack myelin [13][14]. When cannabis is swallowed, it passes through the liver first, which changes how much reaches the blood and how it mixes with other medicines.
THC
What it is: delta-9-tetrahydrocannabinol, the compound in cannabis that changes how you feel.
How it may work in MS: it partly switches on CB1 and CB2 receptors and shifts the balance between glutamate, which excites nerves, and GABA, which calms them — one way it can relax muscles [2].
The catch: the same action on the brain brings dizziness, sleepiness and changes in thinking.
CBD
What it is: cannabidiol, a compound that does not cause a high.
How it may work in MS: it acts differently at CB2 receptors and can soften the unwanted mental effects of THC, which is one reason many products combine the two [2].
The catch: at high doses it affects the liver and how other medicines are cleared.
Research also points to the spinal cord and brainstem, where cannabinoids act on the circuits behind spasticity, and to the nervous system’s control of blood vessels and muscle tone — a possible reason why people often feel better on cannabis while doctor-measured stiffness changes less [13].
Does cannabis help MS symptoms?
Possibly, for some symptoms in some people — and the evidence is mixed. Observational studies of a THC–CBD mouth spray report that many people with stubborn spasticity feel better, but the largest recent placebo-controlled trial of THC, CBD and their combination found no clear difference from placebo on pain or spasticity [3][2]. The people studied were adults with moderate to severe MS spasticity or central nerve pain whose symptoms had not settled on other medicines. Doses on this page are the ones given in studies, not advice.
Choose a symptom to see what was tested.
Spasticity
A 2023 multicenter randomized trial gave THC, CBD or both — up to 22.5 mg of THC and 45 mg of CBD a day for 6 weeks — to 134 people, 119 of them with MS [2]. A review of real-world use of the THC–CBD spray nabiximols pooled 14 publications with 3,989 patients [3].
The trial found no clear difference from placebo. In the real-world data, 41.9% to 82.9% of people starting the spray had at least 20% less spasticity at 4 weeks, at an average of 5 to 6 sprays a day [3] — but those studies had no placebo group.
The most studied symptom, and still unsettled: people often report relief that a placebo-controlled trial did not confirm.
Nerve pain
Central neuropathic pain — pain from damage inside the brain or spinal cord — was a main outcome of the same 2023 trial [2].
A well-designed trial, smaller than planned; none of THC, CBD or the combination beat placebo on average pain [2].
Worth a conversation if usual nerve-pain medicines fall short; not an established pain treatment in MS.
Sleep
A 2026 sleep-lab study recorded the sleep of adults with MS before and after a 6-week course of nabiximols [5].
Self-rated sleep quality (PSQI, where lower is better) improved by 1.28 points (95% CI 0.88–1.67), and measured sleep efficiency rose by 1.57 (95% CI 1.18–1.95) [5]. There was no placebo group.
Promising and small. Sleepiness in the daytime is a side effect, not the same as better nights.
Bladder and walking
A 2026 meta-analysis of 25 studies with 2,949 patients looked at symptoms beyond spasticity in people using nabiximols as an add-on [6].
Compared with each person’s starting scores, bladder function improved (mean difference −16.38, 95% CI −22.18 to −10.58), as did sleep disruption, spasm quality and walking measures [6]. The authors rated the certainty of this evidence very low.
A before-and-after signal, not proof: without a placebo, part of the change can be expectation or natural ups and downs.
How big is the effect in the largest recent trial?
How to read it: each row compares one product with placebo in the 2023 randomized trial [2]. ● estimate · ━ likely range (95% CI) · │ no difference. A row whose range crosses the line shows no clear difference. The numbers, in rating-scale points, sit in the right-hand column.
Pain intensity
Spasticity intensity
Show as a table
| Comparison | Difference | Likely range (95% CI) | p |
|---|---|---|---|
| Pain: THC vs placebo | 0.42 | −0.54 to 1.38 | 0.74 |
| Pain: CBD vs placebo | 0.45 | −0.47 to 1.38 | 0.74 |
| Pain: THC and CBD vs placebo | 0.16 | −0.75 to 1.08 | 0.74 |
| Spasticity: THC vs placebo | 0.24 | −0.67 to 1.45 | 0.89 |
| Spasticity: CBD vs placebo | 0.46 | −0.74 to 1.65 | 0.89 |
| Spasticity: THC and CBD vs placebo | 0.10 | −1.18 to 1.39 | 0.89 |
One more piece of the puzzle comes from outside MS. In a 2026 crossover pilot trial in 16 people with chronic spinal cord injury, a 1:1 THC–CBD oil at up to 12 mg of THC a day lowered self-rated spasticity on a visual scale (−13.9 points, 95% CI −25.5 to −2.3), while the doctor-measured Ashworth score showed no clear difference (−1.2, 95% CI −5.9 to 3.5) [15]. The gap between what people feel and what an exam measures shows up again and again in this field.
Can cannabis slow MS progression?
No. The best test of this question is the CUPID trial: 498 people with progressive MS were randomly assigned to dronabinol, a prescription form of THC, at up to 28 mg a day, or to placebo, and followed for 36 months [16]. Disability, MRI lesions and brain shrinkage changed at the same pace in both groups. The authors note that disability grew more slowly than expected in everyone and many people stopped early, which made small effects harder to detect — but there was no sign of a meaningful one [16].
Did dronabinol slow MS in the CUPID trial?
How to read it: each row compares how often something happened on dronabinol with placebo over three years [16]. ● estimate · ━ likely range (95% CI) · │ no difference. A row whose range crosses the line shows no clear difference.
Show as a table
| Outcome | Measure | Result (95% CI) | p |
|---|---|---|---|
| Disability getting worse (EDSS) | Hazard ratio | 0.92 (0.68–1.23) | 0.57 |
| New or growing T2 lesions | Odds ratio | 1.05 (0.59–1.88) | 0.87 |
| New T1 lesions | Odds ratio | 0.89 (0.50–1.58) | 0.70 |
| Brain volume change | Mean difference, % | −0.01 (−0.26 to 0.24) | 0.94 |
| Physical impact score (MSIS-29-PHYS) | Mean difference, points | −0.9 (−2.0 to 0.2) | 0.11 |
In animals
What was tested: in animal experiments, the cannabinoid acids CBDA and THCA at 10 mg/kg a day in mice with an MS-like disease (EAE) [17], and VSN16R, a drug developed from cannabinoid research that opens a potassium channel in nerve cells rather than acting on CB1 or CB2 [18].
What changed: the acids lowered activation of brain immune cells by about half and of astrocytes by about 30% [17]; VSN16R controlled spasticity in mice without sedation, with a 1,000-fold gap between the working dose and one that affects normal muscle tone [18].
What it means: leads worth testing, in animals only.
In people
What was tested: dronabinol for three years in progressive MS (CUPID) [16].
What changed: nothing measurable in disability, lesions or brain volume compared with placebo [16].
What it means: cannabis is a symptom question, not a disease-modifying treatment. MS medicines that slow the disease stay in place.
Animal results do not transfer to people: an MS-like disease induced in mice is not MS, and doses per kilogram do not translate to a human dose.
What the research shows, from strongest to weakest
Not all studies count the same. A randomized trial — where chance decides who gets the product and who gets a placebo — answers “does it work?” far better than a survey or a mouse experiment. Here is what exists for cannabinoids and MS at each level, with background studies clearly marked.
| Level | What exists for MS | What it can and cannot tell you |
|---|---|---|
| Trials in people | A 2023 placebo-controlled trial of THC, CBD and both for pain and spasticity [2]; the three-year CUPID trial of dronabinol in progressive MS [16]; a 2026 meta-analysis of nabiximols for other symptoms [6]. | Shows effects and side effects under fair comparison. The recent trials found no clear benefit over placebo; the meta-analysis rests on before-and-after data. |
| Observational studies | Real-world studies of the nabiximols spray [3], a UK registry of cannabis-based medicines in MS [19], sleep-lab and daily-diary studies [5][4], and studies of cannabis use and thinking [20]. | Shows how people do in everyday care. Without a comparison group it cannot separate the product from expectation and natural ups and downs. |
| Animal and lab work | Mouse studies with an MS-like disease and cell studies of myelin-making cells [17][21][22]. | Explains why scientists are interested; says nothing yet about patients. |
Browse the studies yourself
Every study cited on this page, in plain words. Neutral and negative results are included.
THC, CBD or both for nerve pain and spasticity
134 people, 119 with MS, took up to 22.5 mg THC and 45 mg CBD a day for 6 weeks; no product beat placebo on pain or spasticity, and 72.4% had a possibly or certainly drug-related side effect [2].
CUPID: dronabinol for progressive MS
498 people for 36 months at up to 28 mg a day; disability worsened at the same pace as on placebo (hazard ratio 0.92, 95% CI 0.68–1.23) [16].
THC–CBD oil for spasticity after spinal cord injury
16 people at up to 12 mg THC a day rated their spasticity lower (−13.9, 95% CI −25.5 to −2.3), but the doctor-measured score did not change clearly [15].
CANSEP: cannabinoids against standard MS symptom treatments
The plan for a randomized trial comparing THC, CBD and their combination with usual treatments for MS symptoms; it reports design, not outcomes [23].
Nabiximols beyond spasticity
25 studies with 2,949 patients: bladder, sleep, spasm and walking scores improved from baseline, and long-term global improvement had an odds ratio of 1.69 [6].
The THC–CBD spray in daily practice
14 publications, 3,989 patients with treatment-resistant spasticity; 41.9–82.9% were early responders at 4 weeks [3].
The endocannabinoid system and leftover symptoms in stable MS
Describes an early clinical program of about 2,500 MS patients, 660 of them treated for at least 6 months, and argues for symptom-focused use [14].
Cannabinoids and motor control
Maps where cannabinoid receptors sit in movement circuits and why this matters for spasticity; mixed conclusions [13].
CBD and other non-intoxicating cannabinoids for brain inflammation
Reviews lab evidence on brain immune cells across several diseases, MS among them; most findings come from cells and animals [8].
Nitrosative stress and the endocannabinoid system
A general review of inflammation chemistry in age-related disorders; not a test of cannabis in MS [24].
Nabiximols and sleep structure
Sleep quality and measured sleep efficiency improved after 6 weeks, without a placebo group [5].
Substance use and same-day symptoms
People with MS logged symptoms through the day; fatigue was higher after cannabis use, while caffeine went with less fatigue [4].
Substance use and moment-to-moment thinking
Looked at whether thinking dipped after cannabis and other substances; results were mixed [25].
Pain medicines and how well they work
Of 1,691 people with MS, 899 had regular pain; 40.2% had stopped at least one medicine, most often because of side effects [1].
Medicines and thinking skills in MS
Compared common medicine classes with several areas of thinking; links went both ways [26].
Cannabis use and thinking in a large clinic sample
People with MS who used cannabis did worse on objective thinking tests than those who did not [20].
UK Medical Cannabis Registry: MS patients
People prescribed cannabis-based medicines reported better symptom and quality-of-life scores over follow-up; no comparison group [19].
Genetic risk for depression and MS course
Tested whether a polygenic score for depression tracks with relapses and disability worsening [11].
Genetic risk for anxiety in MS
Linked a polygenic score for anxiety with anxiety diagnosed alongside MS [12].
One gene and many brain disorders
Screened a single gene against dozens of conditions, including substance use; context for genetics, not for treatment [27].
A non-sedating spasticity drug from cannabinoid research
VSN16R controlled spasticity in mice without sedation; the first human safety trials enrolled men only [18].
Cannabinoid acids and brain inflammation
CBDA and THCA calmed immune cells in mice with an MS-like disease and cut an inflammation marker by 40–90% in cells [17].
Protecting myelin-making cells
Switching on CB1 and GPR55 receptors protected human myelin-making cells from a toxin in a dish [21].
CB1 receptors and the blood-brain barrier
In mice, CB1 receptors on astrocytes helped drive leaks in the blood-brain barrier during inflammation — a reminder that effects can cut both ways [22].
No studies of this type are cited on this page.
What kinds of studies is this evidence built on?
How to read it: each row is one kind of study, and the bar shows how many published studies on cannabinoids and MS are of that kind. Stronger designs are at the top. Gray bars are commentary, animal and lab work, which cannot answer whether something helps patients.
Show as a table
| Design | Studies |
|---|---|
| Meta-analyses | 13 |
| Systematic reviews | 24 |
| Randomized trials | 59 |
| Crossover randomized trials | 4 |
| Other clinical trials | 15 |
| Cohort studies | 67 |
| Case-control studies | 8 |
| Cross-sectional studies | 11 |
| Surveys | 15 |
| Case reports | 13 |
| Narrative reviews | 223 |
| Animal studies | 27 |
| Cell and lab studies | 16 |
| Who was studied | Studies |
|---|---|
| People in clinical trials | 173 |
| People observed, not treated | 290 |
| Whole populations | 37 |
| Animals | 28 |
| Cells and molecules | 6 |
| Not classified | 103 |
Which cannabinoids were studied for MS?
“Cannabis” in MS research means very different things: THC, the compound that changes how you feel; CBD, which does not cause a high; products that combine the two; raw cannabinoid acids; and prescription medicines made from or modeled on THC. A result for one does not carry over to another — the dizziness of THC says nothing about a CBD-only oil, and a trial that found no clear difference for one product says nothing final about a different one.
| Substance | What was studied | Design | What came out |
|---|---|---|---|
| Dispensary products (with a medical card where your state allows) | |||
| THC | Nerve pain and spasticity, up to 22.5 mg a day for 6 weeks [2]. | Randomized trial | No clear difference from placebo; side effects common [2]. |
| CBD | The same trial, up to 45 mg a day [2]; brain inflammation in lab models [8]. | Randomized trial; lab studies | No clear difference from placebo in people; anti-inflammatory effects in cells and animals only. |
| THC + CBD combinations | The combined arm of the 2023 trial [2]; a 1:1 oil in spinal cord injury [15]. | Randomized trials | No clear difference in MS; self-rated spasticity improved in the small spinal cord injury pilot [15]. |
| Cannabinoid acids (THCA, CBDA) | Brain inflammation in mice with an MS-like disease [17]. | Animal and cell studies | Calmer immune cells in animal experiments; never tested in people with MS. |
| Prescription medicines (by prescription, not through a card) | |||
| Dronabinol (Marinol, Syndros) | Slowing progressive MS, up to 28 mg a day for 36 months [16]. | Randomized trial | No slowing of disability [16]. FDA-approved for chemotherapy nausea and AIDS-related weight loss, not for MS [28]. |
| Nabilone (Cesamet) | A synthetic THC-like medicine tried for MS spasticity and pain in small studies. | Small trials | Sedation is common. FDA-approved only for chemotherapy nausea [28]. |
| Nabiximols (Sativex) | A THC–CBD mouth spray for spasticity, bladder, sleep and walking [3][6]; an early clinical program of about 2,500 MS patients [14]. | Trials, observational studies, meta-analysis | The most studied cannabinoid in MS. Approved for MS spasticity in some countries outside the US [9]; not FDA-approved [28]. |
Ways to use cannabis: what each form avoids
Cannabis is not only smoked. In MS studies it was mostly given as a spray inside the cheek or taken by mouth, not inhaled [3][2]. Outside studies, people also vape it, swallow it as gummies or capsules, hold drops under the tongue or apply it to the skin. Each form avoids some risks and keeps others. This section explains the differences; it does not recommend a form.
How is it used, or how would it be?
Choose the closest; most people combine more than one.
Specific to smoking
Joints, blunts, pipes and bongs burn plant material, and the smoke irritates the throat and lungs. The effect starts within minutes and fades within hours, and the dose is hard to measure. Smoking is a risk factor for MS itself and for faster worsening, which is one more reason neurologists ask about it [7].
Specific to vaping and dabbing
Dry-herb vaporizers, oil pens and cartridges avoid burning, but hot vapor still travels the same airways. Concentrates used for dabbing, such as wax, shatter or rosin, are very strong, which makes dizziness and unsteadiness more likely.
Shared devices
A pipe, vape or joint passed between people also passes on colds and other infections — and an infection with fever can bring back old MS symptoms for a while.
Specific to edibles and capsules
Gummies, chocolates, drinks, capsules and swallowed oils avoid smoke entirely. They act slowly and last for hours, and the liver processes them before they reach the blood. The classic mistake is a second piece “because the first did nothing,” which can end in hours of dizziness.
Specific to tinctures and sprays
Drops held under the tongue and sprays inside the cheek avoid the lungs and are measured by the drop or spray; nabiximols, the most studied product in MS, is a cheek spray [3]. Part of the dose is still swallowed.
Specific to topicals and patches
Creams and balms act mainly where they are applied and have not been studied for MS spasticity or nerve pain, which start in the brain and spinal cord. Transdermal patches are different: they deliver cannabinoids into the blood, so their effects and interactions count like any other form.
Specific to prescription cannabinoids
Dronabinol and nabilone are capsules with an exact dose, prescribed by a doctor and filled at a pharmacy, not bought with a medical card. Neither is FDA-approved for MS [28], and they carry the same dizziness and sleepiness as THC.
True of every form
- THC can cause dizziness and unsteadiness, which matter more when MS already affects balance and walking.
- It can add to the sleepiness of muscle relaxants, nerve-pain medicines and sleeping pills.
- Whatever reaches the blood is handled by the liver, especially high-dose CBD.
- No driving after use; in the 2023 trial, driving was not allowed during treatment [2].
Choosing a form is a conversation for the appointment.
All forms as a table
| Form | What it avoids | What remains |
|---|---|---|
| Smoking | Delay in onset | Smoke in the airways, shared devices, hard-to-measure dose, all effects of THC |
| Vaping & dabbing | Burning plant material | Hot vapor in the airways, very strong concentrates, shared devices, all effects of THC |
| Edibles & capsules | Smoke and vapor, shared devices | Slow, long effect, risk of a repeat dose, liver processing, interactions |
| Tinctures & sprays | Smoke and vapor, shared devices | Effects on the brain, partly swallowed dose, interactions |
| Topicals | Most effects on the brain | Skin reactions; not studied for MS symptoms |
| Transdermal patches | Smoke, vapor and swallowing | Effects on the brain, interactions, the same fall risk |
| Prescription cannabinoids | Unknown product content | Dizziness, sleepiness, interactions; not approved for MS |
What science doesn’t know yet
MS has more trials of cannabinoids than most conditions, and the open questions are still big. The authors of these studies list them themselves.
- Trials fall short of their size. The 2023 trial aimed for 448 patients and randomized 134, slowed by recruitment problems and the COVID-19 pandemic [2]. A smaller trial can miss a modest real effect.
- Trials are short. Most last weeks, while MS unfolds over decades. CUPID ran for three years, but slower-than-expected worsening and many dropouts reduced what it could detect [16].
- Real-world data are hard to read. Observational studies of the spray carry reporting bias, loose definitions of response, incomplete follow-up and mixed patient groups [3]; the 2026 meta-analysis adds high variation between studies and no control groups [6].
- What people feel and what doctors measure disagree. Self-rated spasticity can improve while exam scores do not [15], and nobody yet knows which one predicts a better life.
- Dispensary products are not study products. MS research mostly used a standardized spray or fixed doses, while dispensary products differ in strength and ratio from one batch to the next.
- Long-term safety is thin, and women are under-studied in early work. The first human trials of a new spasticity drug enrolled men only because data on safety in pregnancy were incomplete [18].
Side effects of cannabis in MS: what the trials recorded
Side effects are where cannabis research in MS is most consistent. They are usually mild to moderate, they show up early, and they hit exactly where MS already makes life hard: balance, energy and thinking. Researchers advise raising the dose slowly and watching for dizziness, fatigue and mental changes; in MS trials the dose was built up step by step over weeks for that reason.
Other trials tell a similar story. In the three-year CUPID trial, people on dronabinol reported a median of 11 adverse events each, against 10 on placebo [16]. In the small spinal cord injury pilot, 5 of 16 people (31.25%) had non-serious side effects on THC–CBD oil, against 1 of 16 (6.25%) on placebo [15].
Dizziness and falls
The most common complaint with THC-containing products. With weak legs or poor balance, a moment of dizziness on the way to the bathroom at night is how a fall happens.
Fatigue and sleepiness
MS fatigue and drug sleepiness add up. In a daily-diary study of people with MS, fatigue was higher after cannabis use [4].
Thinking and memory
MS can slow thinking on its own. In a large clinic sample, people with MS who used cannabis did worse on objective thinking tests [20].
Mood and psychiatric symptoms
Anxiety, low mood and, rarely, paranoia or psychosis can appear or worsen with THC. Researchers list psychiatric symptoms among the things to monitor.
Liver (high-dose CBD)
High doses of CBD can raise liver enzymes, so liver tests are advised when CBD is taken in large amounts — especially alongside other medicines the liver handles.
Driving
THC slows reaction time. In the 2023 trial, people were not allowed to drive or use cutting tools while on treatment [2].
Drug interactions to discuss with your neurologist
People with MS often take several medicines at once: a disease-modifying therapy, a muscle relaxant, a nerve-pain medicine, something for the bladder, mood or sleep. Reviews of cannabinoids in MS ask doctors to watch for interactions, dependence when opioids are involved, and added side effects with sedatives, anticonvulsants and antidepressants.
Open each one. This is what the studies recorded, not a complete list.
Muscle relaxants (baclofen, tizanidine) mechanism only
Both relax muscles by calming the nervous system, and both cause drowsiness and weakness on their own. THC adds to that: more sleepiness, wobblier legs. People in the MS trials often took cannabinoids on top of these medicines because spasticity had not settled [2]. Do not stop baclofen suddenly to try cannabis — stopping it abruptly is dangerous.
Nerve-pain medicines (gabapentin, pregabalin) and other anticonvulsants noted in MS studies
Anticonvulsants are among the medicine groups reviewers name when they ask for monitoring of added side effects. Together with THC, expect more dizziness and sleepiness; CBD can also change blood levels of some seizure medicines through the liver.
Antidepressants noted in MS studies
Depression is common in MS, and many people take an antidepressant. Reviewers list antidepressants among the medicines to monitor with cannabinoids; THC can also shift mood in both directions. Your physician checks each one by name.
Opioids noted in MS studies
Opioids plus cannabis add sedation and raise the risk of physical and psychological dependence. The 2023 trial excluded people on opioids altogether [2], so there are no trial data on this pairing in MS.
Sedatives and sleeping pills noted in MS studies
Benzodiazepines, sleeping pills and sedating antihistamines add their drowsiness to cannabis. Together they raise the risk of confusion, slowed breathing and falls.
High-dose CBD and the liver noted in MS studies
Liver tests are advised with high-dose CBD. Because the liver also clears many other medicines, CBD can raise or lower their levels; this matters most for medicines with a narrow safe range.
Disease-modifying therapies (DMTs) not tested
The studies on this page did not test interactions between cannabinoids and individual MS therapies. Some DMTs affect the liver or are cleared by it, so your neurologist checks them one by one. Never pause a DMT to “see whether cannabis works.”
Bring the complete list — prescriptions, over-the-counter sleep aids, supplements and anything taken “only sometimes” — to the appointment. That list, more than the diagnosis, decides whether cannabis is reasonable to try.
Who should not use cannabis for MS symptoms
For some people the answer is “not now” or “not at all,” whatever the symptom. MS trials routinely exclude these groups, so there is no evidence of safety for them.
- A history of psychosis — hallucinations or delusions; THC can bring them back or make them worse. See cannabis and psychosis.
- Pregnancy or breastfeeding — trials exclude it, THC passes to the baby, and even early safety work on new spasticity drugs was limited to men for this reason [18].
- Frequent falls in recent months, or walking that already depends on a cane or walker without supervision.
- Several sedating medicines already — opioids, benzodiazepines, sleeping pills, high doses of muscle relaxants.
- Liver disease, especially if high-dose CBD is being considered.
- Driving or using tools while dosing — in the 2023 trial both were off-limits during treatment [2].
- Under 18 — the MS trials studied adults only.
Talk to a licensed physician about whether any of these apply
Is multiple sclerosis a qualifying condition for a medical card?
In many states, yes — multiple sclerosis is one of the conditions most often named on medical cannabis lists, sometimes written as “multiple sclerosis,” sometimes as “severe and persistent muscle spasms, including those characteristic of MS.” Still, it depends on your state. Every program keeps its own list, and a physician has to match your diagnosis to that list, not to a symptom.
Where MS is not named, spasticity, chronic pain or a broader “debilitating condition” clause may apply, and some states let a physician certify any condition they judge serious enough. The lists change as legislatures and health departments update them, so the current wording for your state is the one that counts. The physician confirms it at the evaluation, using your records.
MS is named in your state
The simplest case. Bring a neurologist’s note with the diagnosis and the physician evaluates you against that listed condition.
Spasticity or chronic pain is listed
Muscle spasms, spasticity or chronic pain may be on the list even where MS is not named. What counts is a diagnosis in your records.
Neither is on the list
A card may not be available yet where you live. Some states let physicians certify other debilitating conditions or accept petitions to add new ones.
What else has a doctor diagnosed?
State lists name diagnoses, not symptoms — pick what is in your records.
Muscle spasms: severe or persistent spasms are on many lists, often with MS named as the example. Read muscle spasms and medical cannabis.
Chronic pain: the most widely listed condition across state programs, and MS nerve pain often fits it. Read chronic pain and medical cannabis.
Seizures or epilepsy: seizures are more common in MS than in the general population, and seizure disorders are on most lists; note the CBD and seizure-medicine interaction above. Read seizures and epilepsy and medical cannabis.
Insomnia: a diagnosed sleep disorder is listed in some programs. Read insomnia and medical cannabis.
Depression: common in MS; fewer states list it, and THC can affect mood in both directions. Read depression and medical cannabis.
Anxiety: several states list anxiety disorders or accept them under broader wording. Read anxiety and medical cannabis.
Migraine: listed in some states; migraine can also cause spots on an MRI. Read migraine and medical cannabis.
None of these: then the decision rests on your state’s wording for MS and the physician’s judgment. Start with your state’s medical marijuana laws.
What documents help at the appointment
- A neurologist’s note or letter that names the diagnosis and, if known, the type of MS.
- Your latest MRI report — the written report, not the images.
- A list of every medicine with doses, including your DMT, muscle relaxants and nerve-pain medicines.
Medical card or recreational purchase
In states with adult-use sales, adults can buy without a card. A card still changes several things, though the details are set state by state.
| Aspect | With a medical card | Recreational |
|---|---|---|
| Taxes | Often lower; some states waive part of the cannabis tax for patients | Full state and local cannabis taxes |
| Purchase and possession limits | Often higher; depends on your state | Set for adult-use buyers |
| Products | Medical dispensaries and, in some states, medical-only products | Adult-use product range |
| Age | Patient age rules set by each program | Adult-use age limit set by the state |
| Physician involvement | A licensed physician reviews your conditions and medicines | None |
| Document | State card or recommendation, recorded in a confidential registry | Government ID only |
In states without adult-use sales, the medical program is the only legal way to buy at a dispensary at all.
Will a card save you money?
It can, but only where your state taxes patients less than recreational buyers, and the amount depends on your state’s tax rates and how much you buy. Weigh that against the evaluation fee and any state registration fee. The breakdown is in medical vs. recreational cannabis taxes, and the wider differences in medical and recreational cannabis compared.
Your state’s facts: legal status, possession limits, taxes and home growing
Four facts decide what a card means in practice where you live. They differ from state to state and change with new laws, so we keep them on each state’s own page rather than copying numbers here:
- Legal status — medical only, or medical plus adult use.
- Possession limits — how much a patient may buy and carry, often more than for recreational buyers.
- Taxes — whether patients skip part of the cannabis tax.
- Cultivation — whether patients may grow plants at home, and how many.
All four are listed state by state on the laws and regulations pages.
What the program in your state involves
Qualifying is the first of two steps. In most states a physician’s recommendation is followed by registration with the state health department, which issues the card and enters you in a confidential patient registry; in a few, the recommendation itself is what a dispensary asks for. Purchases happen at licensed dispensaries, some of which deliver. Products there are lab-tested: ask for the certificate of analysis (COA), which shows the measured THC and CBD content, and keep to one product long enough to judge it.
Many state laws also let a patient name a registered caregiver who may buy and handle products on their behalf; who qualifies and how to register is set by each state. Cards from one state are not automatically valid in another — see which states accept out-of-state cards.
Will a medical card affect work, firearms, driving or privacy?
These are the questions that keep many people with MS from asking about cannabis at all. Short, honest answers:
Firearms
Federal law bars anyone who is an “unlawful user” of a controlled substance from having a firearm, and cannabis remains federally controlled, so a state card does not change the federal rule [29]. The federal firearms purchase form asks about this directly. One state’s situation is walked through in owning guns with a medical card in Ohio.
Work and drug tests
Employment protections for card holders differ by state. Some states bar discrimination against registered patients for off-duty use; many employers can still enforce drug-free policies, especially in safety-sensitive and federally regulated jobs. A card does not make it acceptable to be impaired at work.
Driving
Driving under the influence of THC is illegal in every state, card or no card. THC slows reaction time on top of whatever MS already does to vision, strength and reflexes.
Privacy
Your medical records are protected under the HIPAA Privacy Rule [30], and state patient registries are confidential; dispensaries and law enforcement can usually check only whether a card is valid. Your health insurer is not told, because medical cannabis is not billed to insurance.
General information, not legal advice.
What this means if you are considering it
A good evaluation is a conversation about one or two specific symptoms, the medicines you already take and what would count as “better.” It goes faster and safer when the facts are on the table — and it is a normal medical conversation, not something to feel awkward about.
Your situation: where to start
- Recently diagnosed and reading up: start with what MS is and what the studies tested; your neurologist and a DMT come first.
- Spasticity or nerve pain has not settled on your current treatment: use the questions below and check how your situation fits.
- You moved to another state: a card rarely travels with you — see which states accept out-of-state cards and choose your new state.
- You already have a card: see renewing your card.
- You help a family member with MS: how a registered caregiver works is set by each state’s law — see what the program in your state involves.
What to bring to the appointment
Tap each item as you get it ready.
Questions to ask your neurologist
- Could cannabis interact with my DMT, muscle relaxant or nerve-pain medicine?
- THC, CBD or both — and why that choice for my symptom?
- How will we know within a month whether it is helping?
- What should make me stop right away?
- How might it affect my balance and walking?
An evaluation makes sense if
- A specific symptom — spasticity, nerve pain, sleep, bladder — has not settled with the usual treatment.
- You keep your MS therapy and your neurologist in the loop.
- Your full medicine list can be reviewed.
- Your state’s program covers MS or a related diagnosis.
It is not the right step if
- The hope is to slow or reverse MS.
- Symptoms are new and have not been checked by a neurologist.
- There have been several recent falls.
- There is a history of psychosis, or a pregnancy.
This page summarizes published research for education. It does not replace a physician’s advice. Cannabis does not treat MS or slow it, and people taking several medicines face a higher risk of interactions.
How to get a medical card for MS online
Everything happens online, so there is nowhere to travel — which matters when fatigue or walking makes every trip expensive. Four steps take you from the first form to a card in your hand.
Fill in the intake form
Your state, your diagnoses and your current medicines. Have the neurologist’s note ready to upload.
See a physician licensed in your state
A one-on-one appointment online. You agree on the time with the physician; keep an hour free rather than a minute.
Receive your signed recommendation
If the physician approves, the signed recommendation arrives in your account after the appointment.
Register with your state
Where required, you submit the recommendation to the state program, which reviews it and issues the card.
What you end up with
Across 250 reviews from patients in the states where we are licensed. We do not sort them by score and do not hide the low ones.
- 150,000+patients evaluated — everyone who has been through an appointment with us, in every state where we are licensed
- Since 2017doing only this: online evaluations for medical cannabis programs, and nothing else on the side
A recommendation from a physician licensed where you live, and — once your state registers it — a card that lets you buy at licensed dispensaries. Your documents stay in your account and documents, and how the medical card works explains the evaluation in detail. The physicians who see patients are listed on our physicians page.
Programs for veterans and for people with low income are available in some states.
What it costs
The evaluation fee for your state is shown before you pay; a state registration fee, where one exists, is paid to the state separately. Whether a recommendation is issued is the physician’s medical decision. Details are on how the medical card works, and answers about payment are in the medical card FAQ.
Renewing your card
MS is lifelong, so most patients renew. Cards and recommendations expire on a schedule your state sets, and renewal means a repeat evaluation with your updated medicines and any change in your MS treatment. Already have a card? Choose your state at the top of this page; your state’s page covers renewal. Your current documents and expiry date are in your account.
Questions people ask about MS and medical cannabis
Does multiple sclerosis qualify for disability?
It can. The Social Security Administration lists multiple sclerosis in its disability guide for neurological disorders; approval depends on how much MS limits movement, thinking, vision or the ability to work, documented over time [31]. Your neurologist’s records and exam findings carry the most weight.
Can I get pregnant with MS?
Yes. Many people with MS have healthy pregnancies, and relapses often become less frequent during pregnancy, with a higher risk in the months after birth. Some DMTs must be stopped well before trying to conceive, so plan it with your neurologist. Cannabis is not advised in pregnancy or while breastfeeding.
Can MS cause seizures?
Seizures are more common in people with MS than in the general population, though still uncommon. Some MS symptoms, such as brief painful spasms, can look like seizures. If you take a seizure medicine, mention it before any CBD product: CBD can change its levels.
Are antibiotics safe with MS?
Generally, yes, and treating an infection quickly matters, because a fever or a urinary infection can bring back old symptoms or trigger a pseudo-relapse. Some DMTs lower the body’s defenses against infection, so tell any prescriber which MS therapy you take.
Who gets MS?
MS is usually diagnosed in young and middle adulthood, and women are affected considerably more often than men. It is more common far from the equator and in people of Northern European ancestry, though it occurs in every population [7].
What is the ICD-10 code for an MS exacerbation?
There is no separate code for a relapse. Since October 1, 2025, the US ICD-10-CM codes MS by type — for example, G35.A for relapsing-remitting MS — and the old single code G35 is no longer used on its own [32]. Your doctor’s office documents the relapse in the notes alongside the type.
Can I use cannabis with my MS medications (DMTs)?
The studies here did not test cannabinoids with individual DMTs, so nobody can promise it is safe. The bigger known issues are with muscle relaxants, nerve-pain medicines, opioids and sedatives, which add sleepiness and falls. Your neurologist and the evaluating physician should see the full list — and the DMT stays.
Is CBD alone enough for MS?
There is little evidence for it. In the 2023 trial, CBD on its own did not beat placebo on pain or spasticity [2], and most positive MS data come from products that combine THC and CBD. CBD avoids the high but still affects the liver and other medicines.
Is delta-8 THC legal or safe for MS?
Its legal status differs by state, and products sold in shops and online are often loosely regulated, so labels may not match what is inside. Delta-8 acts much like regular THC, with the same dizziness and interaction risks, and it has not been studied in MS.
Can I go to a dispensary right after approval?
It depends on your state. In some, the signed recommendation is enough; in most, you first register with the state and wait for the card or an approval number. The steps for your state are on its page in the list at the top.
Does my card work in another state?
Sometimes. Reciprocity — one state honoring another state’s card — exists in some states and not others, and rules for visitors vary. Check which states accept out-of-state cards and traveling with cannabis before a trip.
What if I lose my card?
Most states let you request a replacement from the program that issued it. The steps are in what to do if your card is lost and the medical card FAQ.
How do I renew my medical card?
Renewal is a repeat evaluation before your card or recommendation expires, with your updated medicines. See renewing your card, or choose your state from the list at the top of this page.
How much does it cost, and what if I’m not approved?
The evaluation fee for your state is shown before you pay; a state registration fee, where one exists, is paid to the state separately. Whether a recommendation is issued is the physician’s medical decision. Details for both are on how the medical card works.
Is an online evaluation legitimate?
Yes, where state law allows telemedicine for medical cannabis evaluations. The appointment is with a physician licensed in your state, one-on-one, and the recommendation is the same document an in-person visit would produce.
Will my employer or insurer know?
Not from us: your records are protected under the HIPAA Privacy Rule [30], and state registries are confidential. Insurance is not billed for medical cannabis. An employer can still learn of use through a drug test; what happens then depends on your state, as explained in work, firearms, driving and privacy.
More research on cannabis and multiple sclerosis
This page cites a selection of studies. Our research library holds every study we track on cannabis and multiple sclerosis, from laboratory work to clinical trials, and lets you filter them by cannabinoid, study type and year.
- studies
- 1,800+
- in people
- 720+
- clinical trials
- 150+
Related brain and nervous system conditions
MS often travels with other diagnoses — spasms, chronic pain, poor sleep, low mood — and some of them are on more state lists. Each page below covers its own research and qualifying rules.
MS resources and latest research
The newest work cited on this page, all from 2026: a meta-analysis of nabiximols beyond spasticity [6], a sleep-lab study of the same spray [5], a spinal cord injury pilot trial of THC–CBD oil [15] and lab studies of cannabinoid acids in an MS-like disease [17]. Each is summarized in browse the studies yourself. For background on how cannabis works in the body, and for new articles as research and laws change:
References
32 sources
- 1. Pain Medication Use and Perceived Effectiveness in People With Multiple Sclerosis: A Mixed-Methods Study. DOI: 10.1155/prm/9981770 PMID: 42525595
- 2. Cannabis-Based Medicine for Neuropathic Pain and Spasticity-A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial. DOI: 10.3390/ph16081079 PMID: 37630995
- 3. Daily Practice Managing Resistant Multiple Sclerosis Spasticity With Delta-9-Tetrahydrocannabinol: Cannabidiol Oromucosal Spray: A Systematic Review of Observational Studies. DOI: 10.1177/1179573519831997 PMID: 30886530
- 4. Daily Temporal Associations Between Use of Psychoactive Substances and Fatigue, Pain, Stress, and Depressive Symptoms in People With Multiple Sclerosis. DOI: 10.1016/j.apmr.2026.01.014 PMID: 41633444
- 5. Nabiximols improves sleep architecture in multiple sclerosis: A prospective polysomnographic study. DOI: 10.1016/j.neurot.2026.e00840 PMID: 41617600
- 6. Nabiximols in Multiple Sclerosis: Beyond Spasticity-An Exploratory Systematic Review and Meta-Analysis of Symptomatic Outcomes. DOI: 10.3390/medsci14030346 PMID: 42506315
- 7. National Institute of Neurological Disorders and Stroke. Multiple Sclerosis. 2025.
- 8. Cannabidiol and other non-psychotropic cannabinoids from Cannabis sativa as therapeutics for microglial-mediated neuroinflammation and neurodegeneration. DOI: 10.1186/s42238-026-00445-5 PMID: 42121212
- 9. National Institute for Health and Care Excellence. Multiple sclerosis: Clinical Knowledge Summaries. 2025.
- 10. National Multiple Sclerosis Society. Types of MS. 2025.
- 11. Depression Polygenicity and Disease Activity and Disability Worsening in Multiple Sclerosis. DOI: 10.1002/ana.70020 PMID: 40772555
- 12. Polygenic liability for anxiety in association with comorbid anxiety in multiple sclerosis. DOI: 10.1002/acn3.52025 PMID: 38715244
- 13. Cannabinoids in Motor Control: From Receptor Distribution to Motor Disorders. DOI: 10.3390/biomedicines14040844 PMID: 42072385
- 14. Enhancing the endocannabinoid system to treat residual disease in relapse-free multiple sclerosis. DOI: 10.3389/fneur.2026.1747131 PMID: 41859417
- 15. Medical cannabis improved self-reported spasticity rating in patients with chronic spinal cord injury: a placebo-controlled, double-blind, crossover pilot clinical trial. DOI: 10.1177/17562864261468464 PMID: 42544174
- 16. Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial. DOI: 10.1016/S1474-4422(13)70159-5 PMID: 23856559
- 17. Anti-Neuroinflammatory Cannabinoid Acids as a New Therapeutic Approach for Multiple Sclerosis. DOI: 10.3390/molecules31071227 PMID: 41976267
- 18. Big conductance calcium-activated potassium channel openers control spasticity without sedation. DOI: 10.1111/bph.13889 PMID: 28677901
- 19. UK Medical Cannabis Registry: An Updated Analysis of Cannabis-Based Medicinal Products for Multiple Sclerosis. DOI: 10.1159/000549178 PMID: 41357430
- 20. Cannabis and Cognitive Function in Multiple Sclerosis: Findings From a Large Consecutive Clinical Sample. DOI: 10.1111/ene.70142 PMID: 40616362
- 21. Neuroprotective Role of Cannabinoid CB1 and GPR55 Receptors in a Cell Model of Multiple Sclerosis. DOI: 10.1007/s12035-026-05780-5 PMID: 41776092
- 22. Astrocyte CB1 receptors drive blood-brain barrier disruption in central nervous system inflammatory disease. DOI: 10.1186/s12974-026-03708-3 PMID: 41606632
- 23. Efficacy of cannabinoids compared to the current standard treatments on symptom relief in persons with multiple sclerosis (CANSEP trial): study protocol for a randomized clinical trial. DOI: 10.3389/fneur.2024.1440678 PMID: 39114536
- 24. Radical Revelations: The Interplay of Nitrosative Stress, the Endocannabinoid System, and Treatment of Age-Related Disorders. DOI: 10.3390/ijms27062813 PMID: 41898672
- 25. Temporal Association Between Reported Use of Psychoactive Substances and Cognitive Function in Individuals With Multiple Sclerosis. DOI: 10.1016/j.apmr.2025.08.005 PMID: 40840668
- 26. Associations between medication use and multiple domains of cognitive function in people with multiple Sclerosis. DOI: 10.1016/j.msard.2025.106854 PMID: 41260151
- 27. Phenome-wide association studies between SERINC2 and neuropsychiatric disorders. DOI: 10.3389/fpsyt.2024.1420395 PMID: 39902246
- 28. U.S. Food and Drug Administration. FDA and Cannabis: Research and Drug Approval Process. 2024.
- 29. Legal Information Institute, Cornell Law School. 18 U.S. Code § 922 – Unlawful acts. 2024.
- 30. U.S. Department of Health and Human Services. The HIPAA Privacy Rule. 2024.
- 31. Social Security Administration. Disability Evaluation Under Social Security: 11.00 Neurological Disorders – Adult. 2024.
- 32. Centers for Disease Control and Prevention, National Center for Health Statistics. ICD-10-CM: International Classification of Diseases, Tenth Revision, Clinical Modification. 2025.